Amylyx Pharmaceuticals (AMLX) has just been removed from several Russell equity indexes, a technical event that can prompt index tracking funds to adjust holdings and influence short term trading patterns in the stock.

Despite the index removals and a 1-day share price return of 1.64% and 7-day share price return of 3.9% at the latest close of $17.97, Amylyx Pharmaceuticals still has a 30-day share price return of 34.91% and a year to date share price return of 57.36%, while the 1-year total shareholder return of 165.83% contrasts with a 3-year total shareholder return that declined 17.91%, indicating stronger recent momentum following a weaker longer-term period.

If this kind of move has you looking beyond a single biotech, it may be a moment to scan for other healthcare names using the 40 healthcare AI stocks

The recent swing in Amylyx Pharmaceuticals after those Russell index removals looks heavily sentiment driven, tied to technical flows rather than fresh fundamentals. How does that square with what the stock now implies about the business?

Most Popular Narrative: 19.1% Undervalued

The most followed valuation narrative for Amylyx Pharmaceuticals points to a fair value of $22.20 versus the last close at $17.97, framing the recent price action in a very different light to short term index flows.

The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.

Want to understand why this narrative supports such a strong gap to fair value? It relies on expectations for steep revenue build, margin lift and a rich future earnings multiple. The tension between today’s losses and those future assumptions is where the discussion on Amylyx Pharmaceuticals becomes more detailed.

Result: Fair Value of $22.20 (UNDERVALUED)

However, the Amylyx Pharmaceuticals story could change quickly if the pivotal LUCIDITY trial disappoints or if post bariatric hypoglycemia adoption and payer coverage are weaker than expected.

Another View on Amylyx Pharmaceuticals Valuation

The earlier discussion leans on future earnings assumptions to argue Amylyx Pharmaceuticals looks undervalued, yet the current P/B of 7.3x is higher than both peers at 4.7x and the wider US Pharmaceuticals industry at 2.4x. That premium points to higher valuation risk if expectations reset.

Next Steps

Uncertain about where sentiment on Amylyx Pharmaceuticals really sits after these mixed signals on valuation and recent trading? Act while the data is fresh and consider both the potential benefits and the concerns by reviewing the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Amylyx Pharmaceuticals?

If Amylyx Pharmaceuticals has you rethinking your watchlist, now is the time to broaden your search and line up a few more candidates worth your attention.

• Target potential bargains by reviewing the 41 high quality undervalued stocks, which combine solid fundamentals with prices that may not fully reflect their strengths.
• Strengthen your income stream by scanning the 8 dividend fortresses, which focus on companies offering higher yields with an eye on durability.
• Reduce portfolio stress by reviewing the 74 resilient stocks with low risk scores, designed to highlight stocks with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.